Ildong Pharmaceutical Co., Ltd. (KRX:249420)
South Korea · Delayed Price · Currency is KRW 27,400
+800 (3.01%)
Apr 8, 2026, 3:30 PM KST
Ildong Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 566,934 | 614,941 | 600,758 | 637,714 | 560,132 |
Other Revenue | - | - | -0 | - | -0 |
| 566,934 | 614,941 | 600,758 | 637,714 | 560,132 | |
Revenue Growth (YoY) | -7.81% | 2.36% | -5.79% | 13.85% | -0.30% |
Cost of Revenue | 347,353 | 381,659 | 387,093 | 401,627 | 340,958 |
Gross Profit | 219,581 | 233,282 | 213,665 | 236,088 | 219,174 |
Selling, General & Admin | 157,965 | 167,539 | 165,116 | 190,252 | 171,296 |
Research & Development | 35,599 | 46,268 | 95,018 | 109,895 | 96,524 |
Other Operating Expenses | 1,304 | 1,262 | 1,216 | 3,814 | 1,087 |
Operating Expenses | 202,258 | 221,851 | 267,082 | 309,754 | 273,586 |
Operating Income | 17,322 | 11,431 | -53,418 | -73,666 | -54,412 |
Interest Expense | -12,173 | -15,938 | -14,725 | -9,788 | -10,556 |
Interest & Investment Income | 942.07 | 1,126 | 1,093 | 1,552 | 569.37 |
Earnings From Equity Investments | 283.69 | -273.49 | -0.36 | -0.54 | -1.67 |
Currency Exchange Gain (Loss) | -47.26 | -1,016 | -748.46 | -475.09 | 168.49 |
Other Non Operating Income (Expenses) | 22,431 | 6,790 | -24,556 | -20,485 | -75,458 |
EBT Excluding Unusual Items | 28,759 | 2,119 | -92,354 | -102,862 | -139,690 |
Gain (Loss) on Sale of Investments | 7,643 | 1,955 | 439.72 | 2,325 | -862.82 |
Gain (Loss) on Sale of Assets | -2,146 | -4,908 | 1,133 | -282.22 | -101.53 |
Asset Writedown | -2,536 | -9,857 | -3,492 | -19,004 | -550.27 |
Other Unusual Items | 33.33 | - | - | - | - |
Pretax Income | 31,753 | -10,692 | -94,273 | -119,823 | -141,205 |
Income Tax Expense | 8,055 | 1,710 | -13,312 | 22,346 | -40,237 |
Earnings From Continuing Operations | 23,698 | -12,402 | -80,961 | -142,170 | -100,968 |
Minority Interest in Earnings | 3,967 | 7,825 | 2,033 | 584.6 | 1,263 |
Net Income | 27,664 | -4,576 | -78,928 | -141,585 | -99,705 |
Net Income to Common | 27,664 | -4,576 | -78,928 | -141,585 | -99,705 |
Shares Outstanding (Basic) | 29 | 28 | 27 | 26 | 24 |
Shares Outstanding (Diluted) | 31 | 28 | 27 | 26 | 24 |
Shares Change (YoY) | 10.01% | 3.34% | 2.61% | 10.76% | -0.00% |
EPS (Basic) | 942.08 | -163.83 | -2920.01 | -5374.53 | -4191.88 |
EPS (Diluted) | 936.77 | -164.00 | -2920.01 | -5379.82 | -4192.00 |
Free Cash Flow | 5,304 | 17,614 | -49,817 | -65,413 | -25,992 |
Free Cash Flow Per Share | 172.61 | 630.60 | -1843.01 | -2483.08 | -1092.76 |
Gross Margin | 38.73% | 37.94% | 35.57% | 37.02% | 39.13% |
Operating Margin | 3.06% | 1.86% | -8.89% | -11.55% | -9.71% |
Profit Margin | 4.88% | -0.74% | -13.14% | -22.20% | -17.80% |
Free Cash Flow Margin | 0.94% | 2.86% | -8.29% | -10.26% | -4.64% |
EBITDA | 39,898 | 37,366 | -25,099 | -44,121 | -25,101 |
EBITDA Margin | 7.04% | 6.08% | -4.18% | -6.92% | -4.48% |
D&A For EBITDA | 22,576 | 25,935 | 28,319 | 29,545 | 29,311 |
EBIT | 17,322 | 11,431 | -53,418 | -73,666 | -54,412 |
EBIT Margin | 3.06% | 1.86% | -8.89% | -11.55% | -9.71% |
Effective Tax Rate | 25.37% | - | - | - | - |
Advertising Expenses | 27,426 | 32,053 | 25,846 | 37,392 | 35,757 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.